| SCHEDULE OF INFORMATION RELATED TO OPERATIONS OF REPORTABLE OPERATING SEGMENTS |
The
following table presents information about the Company’s reportable segments for the six and three months ended June 30, 2025 and
2024:
SCHEDULE OF INFORMATION RELATED TO OPERATIONS OF REPORTABLE OPERATING SEGMENTS
| | |
2025 | | |
2024 | | |
2025 | | |
2024 | |
| | |
Six months ended | | |
Three months ended | |
| | |
June 30 | | |
June 30 | |
| | |
2025 | | |
2024 | | |
2025 | | |
2024 | |
| | |
| | |
| | |
| | |
| |
| Revenue from pathogen prevention and prolong shelf life | |
| 66 | | |
| 61 | | |
| - | | |
| 17 | |
| Cost related to pathogen prevention and prolong shelf life | |
| (582 | ) | |
| (528 | ) | |
| (314 | ) | |
| (221 | ) |
| Operating loss from Pathogen prevention and prolong shelf life | |
| (516 | ) | |
| (467 | ) | |
| (314 | ) | |
| (204 | ) |
| | |
| | | |
| | | |
| | | |
| | |
| Revenue from renewable energy projects | |
| - | | |
| - | | |
| - | | |
| - | |
| Cost related to renewable energy projects | |
| (130 | ) | |
| - | | |
| (59 | ) | |
| - | |
| Operating loss from Renewable energy projects | |
| (130 | ) | |
| - | | |
| (59 | ) | |
| - | |
| | |
| | | |
| | | |
| | | |
| | |
| Professional services | |
| (557 | ) | |
| (631 | ) | |
| (356 | ) | |
| (400 | ) |
| Share base compensation | |
| (2,029 | ) | |
| (260 | ) | |
| (1,988 | ) | |
| (121 | ) |
| Depreciation | |
| (3 | ) | |
| (7 | ) | |
| (1 | ) | |
| (3 | ) |
| Other general and administrative expenses | |
| (217 | ) | |
| (263 | ) | |
| (114 | ) | |
| (119 | ) |
| Total Operating loss | |
| (3,452 | ) | |
| (1,628 | ) | |
| (2,832 | ) | |
| (847 | ) |
| | |
| | | |
| | | |
| | | |
| | |
| Interest of loans | |
| (77 | ) | |
| - | | |
| - | | |
| - | |
| Financing expenses, net | |
| (1,934 | ) | |
| (74 | ) | |
| (1,203 | ) | |
| (79 | ) |
| Other gain | |
| 3 | | |
| 105 | | |
| 3 | | |
| 117 | |
| Changes in fair value of investments measured under the fair value option | |
| (349 | ) | |
| 114 | | |
| (520 | ) | |
| 30 | |
| Net loss | |
| (5,809 | ) | |
| (1,483 | ) | |
| (4,552 | ) | |
| (779 | ) |
|
Operating
loss related to the Company’s reportable segments and the reconciliation of the total net loss attributable to common stockholders
is as follows:
SCHEDULE
OF INFORMATION RELATED TO OPERATIONS OF REPORTABLE OPERATING SEGMENTS
| | |
2024 | | |
2023 | |
| | |
Year ended December 31 | |
| | |
2024 | | |
2023 | |
| | |
| | |
| |
| Revenue from Pathogen prevention and prolong shelf life | |
| 210 | | |
| 263 | |
| Cost related to Pathogen prevention and prolong shelf life | |
| (896 | ) | |
| (1,361 | ) |
| Operating loss from Pathogen prevention and prolong shelf life | |
| (686 | ) | |
| (1,098 | ) |
| | |
| | | |
| | |
| Revenue from N2O emissions Global warming solutions | |
| - | | |
| - | |
| Cost related to N2O emissions Global warming solutions | |
| (350 | ) | |
| (1,788 | ) |
| Operating loss from N2O emissions Global warming solutions | |
| (350 | ) | |
| (1,788 | ) |
| | |
| | | |
| | |
| Professional services | |
| (2,009 | ) | |
| (1,831 | ) |
| Share base compensation | |
| (1,055 | ) | |
| (2,444 | ) |
| Depreciation | |
| (18 | ) | |
| (21 | ) |
| Other general and administrative expenses | |
| (202 | ) | |
| (396 | ) |
| Total Operating loss | |
| (3,284 | ) | |
| (4,692 | ) |
| | |
| | | |
| | |
| Financing (expenses) income, net | |
| (155 | ) | |
| 47 | |
| Other income | |
| 428 | | |
| 985 | |
| Changes in fair value of investments measured under the fair
value option | |
| (1,300 | ) | |
| (714 | ) |
| Net loss | |
| (5,347 | ) | |
| (7,260 | ) |
|
| SCHEDULE OF INFORMATION ON LONG LIVED ASSETS |
|
The
following table presents the locations of the Company’s long-lived assets as of December 31, 2024 and 2023:
SCHEDULE
OF INFORMATION ON LONG LIVED ASSETS
| | |
2024 | | |
2023 | |
| | |
Year ended December 31 | |
| | |
2024 | | |
2023 | |
| | |
| | |
| |
| Israel | |
| 43 | | |
| 102 | |
| United States | |
| 13 | | |
| 21 | |
| Property,
plant and equipment and ROU assets | |
| 56 | | |
| 123 | |
|